Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xueshuantong Injection is a Traditional Chinese Medicine (TCM) preparation composed of the total saponins extracted from *Panax notoginseng* (Burk.) F.H. Chen. It is primarily indicated for the treatment of cardiovascular and cerebrovascular diseases, such as ischemic stroke (cerebral infarction), coronary heart disease (angina pectoris), and retinal vein occlusion. The drug works by promoting blood circulation, removing blood stasis, and improving microcirculation. Its pharmacological effects include the inhibition of platelet aggregation, reduction of blood viscosity, and protection of vascular endothelial cells. The lyophilized powder formulation is frequently utilized in clinical settings for its enhanced stability and standardized dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xueshuantong injection.